Please select the option that best describes you:
When do you recommend SOFT/TEXT strategy of ovarian suppression/aromatase inhibitor in the adjuvant setting in pre-menopausal women?
Is this a recommendation reserved for higher-risk patients (age </= 35 who received chemotherapy), or all pre-menopausal patients?